Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GE11-liposomal CD73 siRNA
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
GE11-liposomal CD73 siRNA is an experimental EGFR-targeted nanoparticle formulation designed to silence the expression of CD73 (ecto-5'-nucleotidase) in the tumor microenvironment. The formulation utilizes the GE11 peptide, which binds specifically to the Epidermal Growth Factor Receptor (EGFR), to facilitate targeted delivery of siRNA-loaded nanoliposomes to tumor cells. By knocking down CD73, the drug reduces the conversion of extracellular AMP to immunosuppressive adenosine, thereby enhancing anti-tumor immune responses, increasing CD8+ T-cell activity, and reducing regulatory T-cell (Treg) infiltration. It has been studied primarily in preclinical models of metastatic breast cancer, often in combination with chemotherapy agents like liposomal doxorubicin.
- Other names
- GE11-Lipo CD73 siRNAGE-11-Lipo CD73 siRNAGE 11-Lipo CD73 siRNAEGFR-Targeted liposomal CD73 siRNA
02
Targets
CD73 (Ecto-5'-nucleotidase)EGFR (Epidermal growth factor receptor)
Beyond the preview
Go deeper on GE11-liposomal CD73 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GE11-liposomal CD73 siRNA.